Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 86769 refers to the laboratory test for the detection of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for coronavirus disease (COVID-19). This test is crucial for diagnosing both current and past infections of COVID-19. The common language description highlights the use of enzyme-linked immunosorbent assays (ELISA), which are sophisticated, multi-step laboratory methods designed to identify the presence of immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies in a patient's serum or plasma. IgG antibodies are typically produced in response to an infection and remain in the body for an extended period, indicating a past infection or a long-term immune response. Conversely, IgM antibodies are the first type of antibody produced during an initial immune response, making them valuable for identifying recent infections. The testing process involves diluting the patient's sample, applying it to microplate wells coated with SARS-CoV-2 recombinant antigens, and following a series of incubation and washing steps. The presence of antibodies is determined through a colorimetric measurement, where a chromogenic substrate reacts with an enzyme-labeled antibody, resulting in a color change that correlates with the concentration of antibodies in the sample. This detailed methodology underscores the importance of the test in both clinical diagnostics and public health monitoring during the COVID-19 pandemic.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The CPT® Code 86769 is indicated for the detection of antibodies to SARS-CoV-2 in patients who may be experiencing symptoms of COVID-19 or have had potential exposure to the virus. The following conditions warrant the use of this antibody test:

  • Diagnosis of COVID-19: The test is utilized to confirm a current or past infection of COVID-19 in patients presenting with symptoms consistent with the disease.
  • Assessment of Immune Response: It helps in evaluating the immune response in individuals who have recovered from COVID-19, providing insight into their potential immunity status.
  • Screening of Asymptomatic Individuals: The test may be performed on individuals who are asymptomatic but have had known exposure to the virus, aiding in public health efforts to monitor and control the spread of COVID-19.

2. Procedure

The procedure for conducting the antibody test using CPT® Code 86769 involves several critical steps to ensure accurate detection of antibodies against SARS-CoV-2. The following outlines the procedural steps:

  • Step 1: Sample Collection - A sample of the patient's serum or plasma is collected, which serves as the basis for the antibody testing. This sample is crucial for the subsequent analysis.
  • Step 2: Sample Dilution - The collected sample is diluted to prepare it for testing. This dilution is necessary to achieve the appropriate concentration for accurate measurement of antibodies.
  • Step 3: Preparation of Microplate Wells - Aliquots of the diluted patient sample, along with control samples, are placed into designated microplate wells that have been pre-coated with SARS-CoV-2 recombinant antigens. This coating is essential for the binding of any antibodies present in the sample.
  • Step 4: Incubation and Washing - The samples are incubated to allow for the binding of antibodies to the antigens. Following incubation, the wells are washed to remove unbound substances, ensuring that only specific antibody-antigen complexes remain.
  • Step 5: Addition of Enzyme-Labeled Antibody - An enzyme-labeled antibody, such as a tracer antibody specific to human IgG and/or IgM, is added to the wells. This antibody will bind to any antibodies that have attached to the antigens, forming a complex.
  • Step 6: Second Incubation - The samples undergo a second incubation period to allow the enzyme-labeled antibodies to bind effectively to the antibody-antigen complexes.
  • Step 7: Colorimetric Measurement - A chromogenic substrate is added, which reacts with the enzyme to produce a color change. The intensity of the color is directly proportional to the concentration of antibodies in the sample.
  • Step 8: Reading Results - A stop solution is added to halt the enzymatic reaction, and the resulting color is measured using a 450 nm microtiter plate reader. The absorbance values are then converted into numeric values to quantify the antibody levels.

3. Post-Procedure

After the completion of the antibody testing procedure, the results are analyzed and reported. It is essential for healthcare providers to interpret the results in the context of the patient's clinical history and symptoms. Positive results may indicate a current or past infection, while negative results may suggest the absence of antibodies. However, further clinical correlation may be necessary, and follow-up testing may be recommended based on the patient's condition and exposure history. Additionally, healthcare professionals should ensure that patients are informed about the implications of their test results, including the potential need for continued precautions against COVID-19, regardless of antibody presence.

Short Descr SARS-COV-2 COVID-19 ANTIBODY
Medium Descr ANTB SEVERE AQT RESPIR SYND SARS-COV-2 COVID-19
Long Descr Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Service Paid under Fee Schedule or Payment System other than OPPS
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) none
MUE 4
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
GW Service not related to the hospice patient's terminal condition
GA Waiver of liability statement issued as required by payer policy, individual case
QW Clia waived test
Q4 Service for ordering/referring physician qualifies as a service exemption
GZ Item or service expected to be denied as not reasonable and necessary
26 Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.
76 Repeat procedure or service by same physician or other qualified health care professional: it may be necessary to indicate that a procedure or service was repeated by the same physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 76 to the repeated procedure or service. note: this modifier should not be appended to an e/m service.
77 Repeat procedure by another physician or other qualified health care professional: it may be necessary to indicate that a basic procedure or service was repeated by another physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 77 to the repeated procedure or service. note: this modifier should not be appended to an e/m service.
95 Synchronous telemedicine service rendered via a real-time interactive audio and video telecommunications system: synchronous telemedicine service is defined as a real-time interaction between a physician or other qualified health care professional and a patient who is located at a distant site from the physician or other qualified health care professional. the totality of the communication of information exchanged between the physician or other qualified health care professional and the patient during the course of the synchronous telemedicine service must be of an amount and nature that would be sufficient to meet the key components and/or requirements of the same service when rendered via a face-to-face interaction. modifier 95 may only be appended to the services listed in appendix p. appendix p is the list of cpt codes for services that are typically performed face-to-face, but may be rendered via a real-time (synchronous) interactive audio and video telecommunications system.
CR Catastrophe/disaster related
CS Cost-sharing waived for specified covid-19 testing-related services that result in and order for or administration of a covid-19 test and/or used for cost-sharing waived preventive services furnished via telehealth in rural health clinics and federally qualified health centers during the covid-19 public health emergency
GV Attending physician not employed or paid under arrangement by the patient's hospice provider
GY Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit
Q1 Routine clinical service provided in a clinical research study that is in an approved clinical research study
XU Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service
Date
Action
Notes
2022-01-01 Note Grammar correction
2022-01-01 Changed Code description changed.
2021-01-01 Added First appearance of addition in code book.
2020-04-10 Added Code added.
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"